Anabolic Steroid Use During Conception & Pregnancy: Risks to Mother & Baby

Anabolic-androgenic steroids (AAS) are contraindicated in pregnancy and strongly discouraged during conception attempts for both partners.

Maternal Risks (Female User)

  • Endocrine: Hypothalamic-pituitary-ovarian axis suppression → anovulation, amenorrhea, infertility.
  • Virilization: Hirsutism, voice deepening, clitoromegaly, acne, male-pattern baldness – often irreversible.
  • Hepatotoxicity: Cholestasis, peliosis hepatis, hepatocellular adenoma/carcinoma (oral 17α-alkylated AAS).
  • Cardiovascular: Dyslipidemia (↓ HDL, ↑ LDL), hypertension, LV hypertrophy, thrombosis.
  • Psychiatric: Aggression, mood lability, dependence, depression on withdrawal.

Fetal Risks (Maternal Exposure)

  • Teratogenicity: Androgen exposure → virilization of female fetus (clitoromegaly, fused labia, urogenital sinus anomalies). Critical window: 8–12 weeks.
  • Growth Restriction: ↓ Birth weight, SGA.
  • Neurodevelopmental: Animal data: altered sexual differentiation of brain, behavioral changes.
  • Long-term: Epigenetic programming → metabolic syndrome, CVD risk (theoretical).

Paternal Exposure

  • Spermatogenesis suppression → oligospermia/azoospermia (reversible after cessation).
  • Sperm DNA fragmentation ↑ → possible embryonic defects, miscarriage.
  • No direct teratogenicity via semen; but fertility impaired.

Guidance

  • Discontinue AAS ≥3–6 months before conception (both partners).
  • Fertility evaluation after washout.
  • If pregnancy occurs on AAS: Immediate cessation; high-risk OB referral; detailed fetal anatomy US; neonatal endocrine follow-up.

AAS use for physique enhancement is incompatible with reproductive health.

Muscle Strains - Related Articles